Parameters of Exercise to Prevent Osteoporosis

Status Completed

Clinical Trial Summary

The principal goal of this study is to determine parameters of walking in terms of peak mechanical vertical force, bout duration, and bout spacing that can preserve or increase bone mineral density (BMD) in postmenopausal women. Release of pulses of parathyroid hormone (PTH), growth hormone (GH), and of markers of bone resorption and bone formation will be used as indicators of the osteogenic effects of a short exposure to exercise. When secreted in pulsatile fashion, GH stimulates osteoblast proliferation, particularly in cortical bone (27, 28). Like GH, the pattern of PTH secretion determines the nature of its effect on bone. When it is secreted in pulsatile manner, PTH contributes to bone formation through activation of bone lining cells, differentiation of osteoprogenitor cells, and suppression of bone cell apoptosis .

Clinical Trial Description

A. Hypotheses and specific aims:

Specific aim 1. Measure plasma concentrations of anabolic hormones (parathyroid hormone (PTH) and growth hormone (GH), at sufficient frequency to define the area under the curve (AUC), and of markers of bone formation (osteocalcin, carboxyterminal propeptide of type 1 procollagen (CICP), and bone-specific alkaline phosphatase (ALKP)), and markers of bone resorption (immunoreactive carboxyterminal telopeptide of type I collagen (CTX)) after 40-minutes of treadmill exercise at the relative intensity of 125% of the ventilatory threshold (VT) corresponding to about 1.78 m/sec (4 miles/h), and two intensities of mechanical loading (724, and 1411 N), in healthy postmenopausal women.

Hypothesis 1. Bone formation, as assessed by increases in markers of bone formation and decreases in markers of bone resorption, will be higher in response to dynamic exercise at a level of mechanical loading that produces increased secretion of PTH and GH than to exercise at other loading intensities.

Specific aim 2. Measure plasma concentrations of anabolic hormones), at sufficient frequency to define the area under the curve (AUC), and of markers of bone formation as in specific aim 1, after two 20-minutes of treadmill exercise, separated by 7 h, at the relative intensity of 125% of the ventilatory threshold (VT) corresponding to about 1.78 m/sec (4 mi/h), and two intensities of mechanical loading (724, and 1411 N), in healthy postmenopausal women.

Hypothesis 2. A 7-hour interval separating the two bouts of exercise will have greater bone anabolic effect than the equivalent volume and intensity of exercise performed in a single bout. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04063813
Study type	Interventional
Source	University of Michigan
Contact
Status	Completed
Phase	N/A
Start date	May 15, 2007
Completion date	August 19, 2010

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03931109` - Circulating miRNA in Primary Hyperparathyroidism
Not yet recruiting	`NCT03232476` - Effect of Mechanical Loading With PTH on Cortical Bone	Phase 4
Completed	`NCT02884401` - Peri-implant Bone Changes in Post-menopausal Osteoporotic Women	N/A
Completed	`NCT00073190` - Patient- and Physician-Based Osteoporosis Education	Phase 1
Completed	`NCT00402441` - Risedronate in the Prevention of Osteoporosis in Postmenopausal Women	Phase 4
Completed	`NCT03710889` - Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption	Phase 3
Completed	`NCT00010712` - Effects of Black Cohosh on Menopausal Hot Flashes	Phase 2
Recruiting	`NCT05058976` - Romosozumab Use to Build Skeletal Integrity	Phase 4
Active, not recruiting	`NCT05405894` - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Recruiting	`NCT03337971` - Nutritional Supplement and Bone Health in Post-Menopausal Women	N/A
Completed	`NCT03701113` - Milk Protein and Bone Health in Postmenopausal Women	N/A
Completed	`NCT01381588` - The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women	N/A
Completed	`NCT00383422` - Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis	Phase 3
Completed	`NCT00549965` - Satisfaction and Compliance of Risedronate in PMO	Phase 4
Completed	`NCT00035256` - Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis	Phase 4
Completed	`NCT01386281` - Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
Completed	`NCT05266261` - Use of Ibandronate in Diabetic Patients	N/A
Recruiting	`NCT04964388` - Effect of GLP-1 Receptor Agonists on Trabecular Bone Score	Phase 2
Active, not recruiting	`NCT03623633` - Comparative Antiresorptive Efficacy Discontinuation of Denosumab	Phase 4
Recruiting	`NCT05575167` - Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Parameters of Exercise to Prevent Osteoporosis — OSTEOPOROSISEX

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms